Objective. Several studies have shown that rituximab may enhance hepatitis C virus (HCV) activity. MicroRNAs (miRNAs) have been implicated in modulating the host immune response in HCV infection; miRNAs can be packaged into the exosomes and then shuttled by the exosomes to aid biologic functions. However, the role of exosomal miRNAs (exo-miRNAs) in rituximab-related HCV activity enhancement remains unclear.
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Objective. Several studies have shown that rituximab may enhance hepatitis C virus (HCV) activity. MicroRNAs (miRNAs) have been implicated in modulating the host immune response in HCV infection; miRNAs can be packaged into the exosomes and then shuttled by the exosomes to aid biologic functions. However, the role of exosomal miRNAs (exo-miRNAs) in rituximab-related HCV activity enhancement remains unclear.
Methods. The association between rituximab and increased HCV activity was examined using an in vitro cell-based assay. Purified exosomes were confirmed using immunoblotting and flow cytometry and quantified using enzyme-linked immunosorbent assay. Exosomal miRNA-155 (exo-miR-155) levels were measured using quantitative reverse transcription-polymerase chain reaction.
Results. In vitro data showed that B cell-derived miR-155 could inhibit HCV replication in hepatocytes through exosome transmission. Rituximab could both induce B cell depletion and affect intracellular miR-155 production as well as exo-miR-155 transmission and then enhance HCV activity in hepatocytes (P < 0.005). Serum exosome levels were increased in rheumatoid arthritis (RA) patients with HCV infection compared with the levels in RA patients without HCV infection (P < 0.01). The exo-miR-155 levels were significantly increased in RA patients with HCV infection compared with those without infection (P < 0.01). A significantly greater decrement of exo-miR-155 expression was observed after rituximab therapy compared with those observed before therapy (P < 0.01), and hepatitis C viral loads increased simultaneously (P < 0.05).
Conclusion. Circulating exo-miR-155 levels were negatively correlated with hepatitis C viral loads and subsequently associated with rituximab-related HCV activity enhancement in RA patients. Exo-miR-155 may become a potential diagnostic biomarker or therapeutic target.
Increasing evidence shows that biologic therapy is effective and can improve the quality of life of patients with rheumatoid arthritis (RA) (1) . A major concern in treating RA patients is biologic agent-induced immunosuppression, particularly in those with chronic hepatitis virus infections. Rituximab is a chimeric monoclonal antibody specific for human CD20 and causes B cell depletion. A previous study by our group demonstrated that rituximab may enhance hepatitis C virus (HCV) activity to a greater extent compared with tumor necrosis factor (TNF) inhibitors (2) . However, the mechanism of rituximab-related HCV activity enhancement remains unclear. MicroRNAs (miRNAs) are endogenous 22-nucleotide noncoding RNAs that mediate messenger RNA (mRNA) cleavage, translational repression, or mRNA destabilization (3, 4) , and currently >2,000 human miRNAs are registered (miRBase Release 20.0) (5) . MiRNAs also have been implicated in modulating the host immune response in infection, including HCV (6, 7) . MiRNA-155 (miR-155) is prominently expressed in B cells and up-regulated in patients with chronic HCV (8) . A recent study showed that immune cells could transmit anti-HCV factors to HCV-infected hepatocytes through exosomes (9) . Based on the findings of rituximab-related HCV activity enhancement and the potential role of miR-155 in HCV infection, we hypothesized that the influence of rituximab may affect the production and transmission of anti-HCV factors (e.g., miR-155) through exosomes and subsequently enhance HCV activity in hepatocytes.
In the current study, we explored the role of exosomal miR-155 (exo-miR-155) in rituximab-related HCV activity enhancement, using an in vitro cell-based assay. Additionally, we investigated the exosome amount and exo-miR-155 levels in serum samples from RA patients with HCV infection who are receiving different antirheumatic therapies compared with those without infection or healthy controls, using an enzyme-linked immunosorbent assay (ELISA)-based exosome quantification assay followed by quantitative reverse transcription-polymerase chain reaction (qRT-PCR) validation.
PATIENTS AND METHODS
Subjects. A total of 40 patients with RA (10) who were scheduled to receive biologic therapy were enrolled from Taichung Veterans General Hospital in Taiwan. Disease activity was assessed using the Disease Activity Score in 28 joints (DAS28) (11) . All patients had persistently active disease, which is defined as a DAS28 of >3.2, after treatment with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs); therefore, biologic therapy based on British Society for Rheumatology guidelines was initiated (12) . RA patients received therapy with adalimumab at a dosage of 40 mg subcutaneously every other week, with golimumab 50 mg once monthly, or with etanercept 25 mg twice weekly. RA patients were prescribed fixed-dose treatment with rituximab (1,000 mg twice with a 14-day interval) at 6-month intervals for a 1-year period. The hepatitis C viral loads in serum were measured before and after biologic therapy. The Institutional Review Board of Taichung Veterans General Hospital approved this study (CE15287B), and written consent from all participants was obtained according to the Declaration of Helsinki.
Exosome isolation and quantification. Samples were centrifuged at 2,500 revolutions per minute for 10 minutes at 4°C to remove cell debris, then filtered through a 0.22-lm filter. The serum-and B cell-derived exosomes were extracted using an ExoQuick exosome precipitation solution (System Biosciences) according to the manufacturer's instructions. The purified exosomes were confirmed using immunoblotting, as described in Supplementary Information, available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/doi/ 10.1002/art.40495/abstract. The exosomes were quantified using a direct ELISA-based method to quantify the exosome surface marker CD63, according to the manufacturer's instructions (System Biosciences).
The B cell origin of exosomes regulating HCV replication was demonstrated by flow cytometric analysis of exosomes, using CD63 in a combination of B cell-and hepatocyte-specific surface markers. Details of the flow cytometric analysis are provided in Supplementary Information.
Exosomal miRNA qRT-PCR. Total exosomal miRNAs (exo-miRNAs) were extracted from the exosomes using TRIzol reagent (Thermo Fisher Scientific) and purified using an RNeasy MinElute Cleanup Kit (Qiagen) according to the instructions of the manufacturer. Twenty-five femtomoles of synthetic Caenorhabditis elegans miRNA (cel-miR-39) (Thermo Fisher Scientific) was added to each sample as the internal control. The purified miRNAs were quantified at optical densities of 260 nm and 280 nm by using an ND-1000 spectrophotometer (NanoDrop Technologies). MiRNA expression was quantified using a TaqMan MicroRNA Assay kit (Applied Biosystems) according to the protocol of the manufacturer.
Statistical analysis. The results are presented as the mean AE SD or the mean AE SEM. The analysis of variance test or Student's t-test was used for between-group comparisons of the expression of candidate miRNAs. P values less than 0.05 were considered significant.
RESULTS
No direct influence of rituximab on HCV replication in hepatocytes. To assess the effects of different biologic agents on HCV RNA replication, we examined HCV replication activity by using an HCV-tricistronic replicon cell system (13) containing luciferase as the reporter, which assays viral RNA replication activity. The HCV replicon cells were treated with individual biologic agents (10 lg/ml). At 72 hours posttreatment, cell viability assays were performed, and HCV RNA replication activity was measured using a luciferase assay. Our results showed no significant difference in cell viability ( Figure 1A ) and HCV genome replication ( Figure 1B ) between HCV replicon cells that were treated with different biologic agents and those that were not treated with biologic agents. Therefore, our results showed that rituximab or TNF inhibitors (adalimumab, etanercept, and golimumab) had no hepatotoxic effect and cannot directly influence HCV replication in hepatocytes.
Possible effect of rituximab on B cell-derived anti-HCV cellular factor transmission to hepatocytes. Because rituximab was directed toward the CD20 antigen on B cells, we further focused on the roles of rituximab and B cells in HCV replication in hepatocytes. Raji cells (B cells; 5 9 10 5 cells/well) were incubated with 10 lg/ml rituximab in the presence of 10% human serum as a complement source. At 1.5 hours posttreatment, the supernatant from Raji or rituximab-treated Raji cell cultures was collected and added to HCV replicon cells. After 72 hours, a luciferase assay of the replicon cells was performed to measure HCV replication activity.
The addition of supernatant from the Raji cell cultures had a significant inhibitory effect on HCV replication ( Figure 1C ), whereas adding rituximab-treated Raji cell cultures to HCV replicon cells rescued HCV replication ( Figure 1C ). To confirm this observation, the Raji cells were treated with rituximab for different periods of time. Supernatant from the rituximab-treated Raji cell cultures was collected at an indicated time and added to the HCV replicon cells. After 72 hours, the replicon cells underwent luciferase assay to determine HCV replication activity. The results showed that rituximab-induced hepatitis C viral replication activity enhancement is timedependent ( Figure 1D ). Based on these observations, we hypothesized that Raji cells may produce HCV replication inhibitors (e.g., miRNAs), and that rituximab may reduce the production or secretion levels of these inhibitors and then cause HCV replication activity enhancement in hepatocytes in a time-dependent manner.
Increased miR-155 expression in peripheral blood cells from RA patients with chronic HCV infection. MiR-155 is prominently expressed in B cells. We performed qRT-PCR In E, symbols represent individual patients. * = P < 0.05; ** = P < 0.01; *** = P < 0.001. RLU = relative luminescence unit; ctrl = control.
to validate miR-155 expression levels in peripheral blood mononuclear cells (PBMCs) from RA patients with or without chronic HCV infection. Our results showed significantly increased miR-155 expression in the PBMCs of RA patients with chronic HCV infection (n = 20) (mean AE SEM 5.46 AE 0.59-fold) compared with those without HCV infection (n = 20) (1.00 AE 0.15-fold; P < 0.001) ( Figure 1E ). Effect of miR-155 on inhibition of HCV replication activity in hepatocytes. To identify the role of miR-155 in HCV replication in hepatocytes, we transfected the miR-155 mimic to the HCV replicon cells and then measured HCV replication activity using luciferase assay. In the miR-155-overexpressing cells, HCV replication activity was significantly suppressed to~60% (P < 0.01) compared with mimic control or nontransfected cells ( Figure 1F ). Conversely, HCV replication activity significantly increased in the miR-155-inhibiting cell (P < 0.05) compared with inhibitor control or nontransfected cells.
Contribution of miR-155 in B cell-derived exosomes to inhibition of HCV replication in hepatocytes. Exosomes released from donor cells (e.g., B cells) can carry cellular components to recipient cells (e.g., hepatocytes), representing a key mode of intercellular communication (14) . To demonstrate that the Raji cell-derived exosome used in this study was of B cell origin, we detected exosome-specific (Alix, TSG101, or CD63) and B cell-specific (CD19) surface markers, using immunoblotting (see Supplementary Figure 1A , available on the Arthritis & Rheumatology web site at http://onlinelibrary. wiley.com/doi/10.1002/art.40495/abstract) and flow cytometry (Supplementary Figures 1B-D) , respectively.
The immunoblotting results showed that CD19 was detected in Raji cell lysates and Raji cell-derived exosomes but not in Huh-7 cells (Supplementary Figure 1A) . Similar results using flow cytometric analysis are illustrated in Supplementary Figures 1B and C. Both CD63 and CD19 were detected in Raji cell-derived exosomes, but the hepatocyte-derived exosome marker asialoglycoprotein receptor 1 (15) was not detected (Supplementary Figure 1D) . Our results validated the notion that isolated Raji cell-derived exosomes were of B cell origin.
To investigate whether miR-155 is a factor in B cellderived exosomes that contributes to the inhibition of HCV replication in hepatocytes, we loaded miR-155 mimic, inhibitor, or control into a Raji cell-derived exosome, using electroporation in accordance with previously published literature (16) . The relative levels of encapsulated miR-155 were determined using qRT-PCR ( Supplementary Figure 2A , available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/doi/10.1002/art.40495/abstract).
Approximately 2.2-fold higher expression of miR-155 in Raji cell-derived exosomes occurred after electroporation with miR-155 mimic in contrast to low miR-155 expression in control loading exosomes or nonloading exosomes (mock), indicating its effective loading by electroporation (P < 0.01). The exosomes were then added to HCV replicon cells. After 48 hours, HCV replication activity significantly decreased in replicon cells with the addition of miR-155 mimic loading Raji cell-derived exosomes compared with those with the addition of control loading exosomes or nonloading exosomes (mean AE SEM 0.52 AE 0.05-fold versus 1.24 AE 0.06-fold versus 1.02 AE 0.06-fold; P < 0.05) (Supplementary Figure 2B) . Conversely, an~0.76-fold decrease in miR-155 levels in Raji cell-derived exosomes occurred after electroporation with the miR-155 inhibitor, causing significantly elevated HCV replication activity in hepatocytes (P < 0.05).
Possible effect of rituximab on HCV replication in hepatocytes through decreasing B cell-derived miR-155 production and exo-miR-155 transmission levels. We hypothesized that the influence of rituximab on responses to B cells may affect the production and transmission of anti-HCV factors (e.g., miR-155) through exosomes and subsequently enhance HCV replication in hepatocytes. We investigated the role of exosomes in intercellular communication between B cells and hepatocytes, using a coculture system (Figure 2A ). Because rituximab treatment caused B cell depletion ( Figure 2B ), we speculated that Raji cellderived exosomal transmission levels may be associated with decreased Raji cell numbers. To exclude interference of rituximab-related B cell number variation, we adjusted the Raji cell numbers post-rituximab treatment to the same as those in non-rituximab treated controls. Raji cells were cocultured with HCV replicon cells at a 1:1 ratio in a Transwell 24-well system with a 0.4-mm porous membrane to prevent the transfer of vesicles larger than exosomes and direct cell contact (Figure 2A) .
After 72-hour coculture, there was no significant difference in cell viability between Raji cells that were and those that were not treated with rituximab after cell number adjustment ( Figure 2C ), but the levels of miR-155 were substantially decreased in rituximab-treated Raji cells (mean AE SEM 0.53 AE 0.04-fold) ( Figure 2D ) compared with untreated cells (0.95 AE 0.07-fold; P < 0.01) or adalimumab (TNF inhibitor)-treated cells (1.11 AE 0.05-fold; P < 0.005), indicating that rituximab directly inhibited miR-155 production in Raji cells. We also observed that Raji cell-derived exo-miR-155 levels in rituximab-treated cells significantly declined (0.55 AE 0.14-fold) ( Figure 2E ) compared with untreated cells (1.01 AE 0.09-fold; P < 0.01) or TNF inhibitor-treated cells (1.03 AE 0.09-fold; P < 0.05). Furthermore, a decrease in the transmission levels of miR-155 from rituximab-treated Raji cells to hepatocytes (0.55 AE 0.14-fold; P < 0.01) ( Figure 2F ) caused increased HCV replication activity (1.37 AE 0.05-fold; P < 0.05) ( Figure 2G ).
LIAO ET AL
Direct effect of rituximab on HCV replication in hepatocytes through decreasing B cell-derived exo-miR-155 levels. To further investigate whether enhancement of rituximab-related HCV activity was directly associated with B cell-derived exo-miR-155, we added purified Raji cellderived exosomes to HCV replicon cells ( Figure 3A) . The results of qRT-PCR showed that the levels of intracellular miR-155 (mean AE SEM 0.67 AE 0.02-fold versus 1.02 AE 0.03-fold; P < 0.005) ( Figure 3B ) and exo-miR-155 (0.72 AE 0.03-fold versus 1.01 AE 0.06-fold; P < 0.05) ( Figure 3C ) from Raji cells treated with rituximab significantly decreased compared with untreated control cells. The , levels of Raji cell-derived exo-miR-155 (E), levels of intracellular miR-155 in HCV replicon cells (F), and HCV replication activity in hepatocytes (G) after 72-hour coculture. Raji cell numbers, adjusted after RTX treatment, were the same as those of the untreated controls. Bars show the mean AE SEM of triplicate experiments. * = P < 0.05; ** = P < 0.01; *** = P < 0.005. See Figure 1 for other definitions.
purified Raji cell-derived exosomes were then added to HCV replicon cells. After 72 hours, we observed significantly decreased miR-155 expression in hepatocytes with the addition of rituximab-treated Raji cell-derived exosomes compared with control (no treatment) (0.63 AE 0.09-fold versus 1.03 AE 0.10-fold; P < 0.05) ( Figure 3D) . Additionally, HCV replication activity significantly increased in replicon cells after the addition of rituximabtreated Raji cell-derived exosomes compared with those after the addition of untreated Raji cell-derived exosomes (mean AE SEM 1.11 AE 0.02-fold versus 1.00 AE 0.01-fold; P < 0.005) ( Figure 3E) .
Increased exosome and exo-miR-155 levels in serum from RA patients with HCV infection. To support the findings of cell-based assay, we further examined the exosome and exo-miR-155 levels in the serum of RA patients with HCV infection. The results of immunoblotting ( Figure 4A ) and exosome quantification using an ELISAbased method ( Figure 4B ) showed increased exosome levels in the serum of RA patients with HCV infection (n = 12) (mean AE SEM 9.72 AE 0.55 9 10 9 exosome particles/ml) compared with those without infection (n = 15) (6.12 AE 1.11 9 10 9 exosome particles/ml; P < 0.01). Additionally, significantly increased exo-miR-155 levels were detected in RA patients with HCV infection compared with those without infection (3.13 AE 1.09-fold versus 1.00 AE 0.19-fold; P < 0.01) ( Figure 4C ).
Significantly decreased exosomal miR-155 expression in RA patients with HCV infection who received rituximab therapy. To investigate the effect of antirheumatic therapy on HCV activity in patients with RA, we enrolled 5 patients who received csDMARDs (60% female, mean AE SD age 67.3 AE 6.6 years), 11 patients who received TNF inhibitor treatment (90.9% female, mean AE SD age 66.1 AE 12.6 years), and 4 patients who received rituximab therapy (all female, mean AE SD age 68.8 AE 9.7 years) ( Table 1) . Because rituximab therapy was available for RA patients in Taiwan who had a poor response or intolerance to therapy with TNF inhibitors, the duration of biologic therapy was longer in patients receiving rituximab therapy compared with that in those receiving TNF inhibitors (4.9 AE 1.9 versus 2.7 AE 2.8 years). However, there was no significant difference in the DAS28 in patients receiving different antirheumatic treatments (csDMARDs versus TNF inhibitors versus rituximab: 3.6 AE 0.5 versus 4.2 AE 0.6 versus 3.6 AE 0.2).
First, we validated the exo-miR-155 expression level in RA patients with HCV infection who received different antirheumatic therapies and demonstrated significantly lower expression of exo-miR-155 in patients who received rituximab treatment compared with those who received TNF inhibitors or csDMARD treatment alone (mean AE SEM 1.47 AE 0.19-fold versus 2.61 AE 0.39-fold or 2.72 AE 0.62-fold; P < 0.05) ( Figure 4D ). The results showed that after treatment, rituximab may enhance the hepatitis C viral load to a greater extent than TNF inhibitors (2.32 9 10 7 versus 1.79 9 10 5 IU/ml; P < 0.05) (Figure 4E) . Additionally, a significantly greater reduction in the expression of exo-miR-155 was observed after rituximab therapy compared with expression before rituximab therapy (0.52 AE 0.03-fold versus 1.00 AE 0.08-fold; P < 0.01) ( Figure 4E ). However, there was no significant difference in exo-miR-155 expression before and after TNF inhibitor therapy. Finally, we monitored the dynamics of hepatitis C viral load and exo-miR-155 levels in the sera of 2 HCV-infected RA patients during the rituximab therapy period. Our results showed that a significant reduction in exo-miR-155 expression in rituximab-treated patients was time-dependent (P < 0.01) (Figure 4F ), and the hepatitis viral loads increased simultaneously.
DISCUSSION
Rituximab, a B cell-depleting agent, was proven to be effective in RA patients who had a poor response to ≥1 TNF inhibitors (17, 18) . Previous studies demonstrated that clinical improvement in rituximab-treated RA patients occurred in association with changes in macrophage function (19) and Th17 cell response (20) . Besides being used in rheumatic diseases, rituximab is widely used for the treatment of non-Hodgkin's lymphoma (NHL). Although some studies showed that rituximab was effective for Relative exo-miR-155 level Figure 4 . Decreased exosomal microRNA-155 (exo-miR-155) in RA patients is associated with RTX-related HCV viremia enhancement. A, Exosome and exo-miR-155 levels in serum from RA patients with HCV infection, as determined by immunoblotting. B, Serum-derived exosome levels in RA patients with chronic HCV infection receiving different antirheumatic drug therapies, RA patients without HCV infection, and healthy controls (HCs), as quantified using enzyme-linked immunosorbent assay. C, Exo-miR-155 levels in RA patients with and those without chronic HCV infection. D, Exo-miR-155 levels in RA patients with chronic HCV receiving different antirheumatic therapies (nonbiologic agent, tumor necrosis factor inhibitor [TNFi], and RTX). E, HCV viral load (left) and exo-miR-155 levels (right) in RA patients before and after receiving RTX or TNFi. F, Dynamics of HCV viral load and exomiR-155 levels in serum from 2 RA patients before and after RTX therapy. Bars show the mean AE SEM of triplicate experiments. * = P < 0.05; ** = P < 0.01; *** = P < 0.005. See Figure 1 for other definitions.
Exo-miR-155 IN RTX-RELATED HCV REACTIVATION
treating patients with HCV-associated cryoglobulinemic vasculitis without influencing HCV viremia (21, 22 ), an increased HCV RNA level during or after rituximab therapy had been reported in NHL patients with HCV infection (23, 24) . Furthermore, a large-scale multicenter study demonstrated that HCV RNA levels significantly increased in patients with diffuse large B cell lymphoma and HCV infection during rituximab-containing chemotherapy (P = 0.006) (25) . In the current study, our clinical data revealed that rituximab may enhance the hepatitis C viral load to a greater extent than TNF inhibitor therapy in patients with RA and chronic HCV infection. Advanced age (mean AE SD 68.8 AE 9.7 years) and a longer duration of rituximab therapy (58.7 AE 22.3 months) were characteristics in the patients who had increased HCV viremia. Our results revealed that B cell-derived exo-miR-155 plays a crucial role in rituximabrelated HCV activity enhancement. A recent study showed that the exosome concentration decreases with advancing age, which was associated with biologic dysfunction in B cells (26) . We hypothesized that aging and long-term rituximab treatment may affect the biologic functions of B cells and cause decreased exosome levels as well as increased HCV viremia. Further large-scale and long-term studies are needed to confirm this hypothesis.
A study by Zhang et al (27) showed that human immune cells recognize HCV-infected cells and respond by producing anti-HCV, which is an important role in HCV infection. In the current study, we demonstrated that adding a supernatant from B lymphocyte cultures has a significant inhibitory effect on HCV replication, indicating that B cells may produce some cellular factors that can inhibit HCV replication in hepatocytes. MiRNAs have been implicated in modulating the host immune response in HCV infection (28, 29) . MiR-155 is encoded within the B cell integration cluster gene and is prominently expressed in B cells (30) . MiR-155 is critical for B cell development and can be up-regulated in B cell receptor (BCR)-stimulated B lymphocytes (31) . A recent study indicated that HCV infection causes up-regulation of BCR signaling (32) . Our results showed significantly increased miR-155 expression levels in the PBMCs of RA patients with chronic HCV infection compared with those without infection, which is consistent with published literature (8) .
We also confirmed that HCV replication activity is significantly decreased in miR-155-overexpressing cells (P < 0.01) compared with mimic control or nontransfected cells. Furthermore, we loaded miR-155 mimic into Raji cell-derived exosomes and then added it to HCV replicon cells. Our results revealed that the HCV replication activity significantly decreases in replicon cells with miR-155 mimic loading B cell-derived exosomes compared with those with control loading or nonloading exosomes (P < 0.05). Taken together, our results showed up-regulation of miR-155 in the PBMCs of patients with RA and chronic HCV infection. Circulating B cellderived exo-miR-155 may transmit to hepatocytes and subsequently inhibit HCV replication. * Except where indicated otherwise, values are the mean AE SD. RA = rheumatoid arthritis; HCV = hepatitis C virus; csDMARDs = conventional synthetic disease-modifying antirheumatic drugs; TNF = tumor necrosis factor; RF = rheumatoid factor; anti-CCP = anti-cyclic citrullinated peptide; DAS28 = Disease Activity Score in 28 joints; ESR = erythrocyte sedimentation rate; CRP = C-reactive protein; NA = not applicable.
LIAO ET AL
Exosomes are extracellular vesicles released by cells that carry proteins, lipids, and nucleic acids, and function in intercellular communication (14) . MiRNAs can be packaged into the exosomes and shuttled by the exosomes to aid biologic functions (33) . Increasing evidence indicates that human immune cells recognize virus-infected cells and respond by producing exosomal miRNAs to play a critical role in viral infection (34) (35) (36) . A previous study showed that B cell-derived miR-155 regulated biologic function in pigment epithelial cells through exosome transmission (37). Zhang et al (38) observed that miR-155 increases in the hepatocytes of patients with chronic HCV infection. Jiang et al (39) demonstrated that miR-155 is a key regulator of antiinflammatory mechanisms that control innate and adaptive immune responses during HCV infection in hepatocytes. Several studies have demonstrated that miR-155 promotes the expression of inflammatory cytokines (e.g., TNF, interleukin-6, interferon-sensitive genes [39] [40] [41] ), which is associated with inhibition of HCV production (42, 43) . We hypothesized that miR-155 inhibits HCV production in hepatocytes possibly by regulating expression of anti-HCV inflammatory cytokines. Relative to B cells, hepatocytes have a very low copy number of miR-155 (30, 44) . In this study, we demonstrated that B cell-derived exo-miR-155 inhibits HCV replication in hepatocytes. These observations may provide novel insights into and prospects for therapeutic targets. Further studies are needed to confirm and extend our findings.
In the current study, we also observed significantly decreased exo-miR-155 expression in RA patients with HCV infection after rituximab therapy compared with that before therapy (P < 0.01). Additionally, our in vitro results also demonstrated that rituximab may inhibit B cell-derived miR-155 production. Previous studies have demonstrated that miR-155 up-regulation in B cells is associated with BCR activation (31, 45) . Kheirallah et al (46) showed that rituximab inhibits BCR signaling. Therefore, we speculated that rituximab decreases miR-155 expression perhaps by inhibiting BCR. In addition, miR-155 transcription is regulated by NF-jB (45, 47) . Jazirehi et al demonstrated that rituximab can diminish IjK activity (48) . A recent study demonstrated that an IjK inhibitor (IjK-16) can decrease miR-155 expression (49) . We speculated that rituximab inhibits miR-155 expression in B cells possibly by diminishing IjK activity and affecting NF-jB signaling. Further in-depth studies are required to confirm our hypothesis.
To our knowledge, this study is the first to investigate the roles of biologic agents and exosomal miRNA in HCV replication activity. Although we present some novel findings, our study has some limitations. First, it was conducted at a single medical center and included a small number of cases. Therefore, the study is not likely to reflect the complete characteristics of chronic HCV infection in RA patients. Second, the characteristics and disease activity of patients receiving different antirheumatic treatments are different. In our study, patients who received rituximab therapy had severe RA with worse cellular immunity and advanced age, which might explain the increased risk of HCV viremia in these patients. However, we validated our observations in patients by using in vitro cell-based assay, which suggests that our results still provide valuable information.
Finally, the exosome isolation protocol used in this study was the polymer-based precipitation method, which may affect the purity of exosomes (50) . Therefore, we validated the purity of the exosome using multiple methods, including immunoblotting, flow cytometry, and CD63-based ELISA for exosome-specific (CD63, Alix, or TSG101) and B cell-specific (CD19) surface marker detection. The results revealed that the exosome is of B cell origin and its purity is good. In addition to assessing serum exosomes, we analyzed Raji cell-derived exosomes to validate rituximabrelated exo-miR-155 expression variation. All results were consistent.
In conclusion, our results showed that B cell-derived miR-155 could inhibit HCV replication in hepatocytes through exosome transmission, as shown in the proposed model ( Figure 5A ). Rituximab could both induce B cell depletion and affect intracellular miR-155 production as well as exo-miR-155 transmission and then cause HCV activity enhancement in hepatocytes ( Figure 5B ). Our results also revealed that circulating exo-miR-155 levels were negatively correlated with HCV viral loads and associated with rituximab-related HCV hyperactivity in RA patients; exo-miR-155 may become a potential diagnostic biomarker or the therapeutic target; confirmation from larger and long-term studies is required. Based on these observations, we concluded that it is important to monitor the HCV viral load in RA patients during the period of specific immunosuppressive therapy and to start an efficient antiviral treatment to prevent the risk of HCV reactivation.
